Health Care
57 companies side by side, each showing its newest quarter, so you can see who is big in the sector and who turns it into profit. That is 59 minus the 2 whose statement we cannot draw; they are listed at the foot of the page.
| Company | Revenue, one quarter | Year over year | Operating margin | Net profit | Net margin |
|---|---|---|---|---|---|
| UNH UnitedHealth Q2 FY26 Year over year +0% Operating margin 7% Net margin 5% | $112.0B | +0% | 7% | $5.5B | 5% |
| CVS CVS Health Q2 FY26 Year over year +7% Operating margin 4% Net margin 3% | $106.1B | +7% | 4% | $3.0B | 3% |
| MCK McKesson Q1 FY27 Year over year +8% Operating margin 1% Net margin 1% | $105.4B | +8% | 1% | $0.6B | 1% |
| COR Cencora Q3 FY26 Year over year +5% Operating margin 1% Net margin 1% | $84.8B | +5% | 1% | $0.8B | 1% |
| CI Cigna Q2 FY26 Year over year +7% Operating margin 4% Net margin 2% | $71.7B | +7% | 4% | $1.7B | 2% |
| CAH Cardinal Health Q2 FY26 Year over year +19% Operating margin 1% Net margin 1% | $65.6B | +19% | 1% | $0.5B | 1% |
| CNC Centene Q2 FY26 Year over year +10% Operating margin 2% Net margin 2% | $53.6B | +10% | 2% | $1.1B | 2% |
| ELV Elevance Health Q2 FY26 Year over year +1% Operating margin 3% Net margin 3% | $50.5B | +1% | 3% | $1.5B | 3% |
| HUM Humana Q1 FY26 Year over year +23% Operating margin 4% Net margin 3% | $39.6B | +23% | 4% | $1.2B | 3% |
| JNJ Johnson & Johnson Q2 FY26 Year over year +7% Operating margin 28% Net margin 22% | $25.3B | +7% | 28% | $5.5B | 22% |
| LLY Eli Lilly Q2 FY26 Year over year +48% Operating margin 39% Net margin 31% | $23.0B | +48% | 39% | $7.1B | 31% |
| HCA HCA Healthcare Q1 FY26 Year over year +4% Operating margin 12% Net margin 8% | $19.1B | +4% | 12% | $1.6B | 8% |
| MRK Merck & Co. Q3 FY25 Year over year +4% Operating margin 38% Net margin 33% | $17.3B | +4% | 38% | $5.8B | 33% |
| ABBV AbbVie Q2 FY26 Year over year +10% Operating margin 38% Net margin 21% | $17.0B | +10% | 38% | $3.6B | 21% |
| PFE Pfizer Q1 FY26 Year over year +5% Operating margin −22% Net margin 19% | $14.5B | +5% | −22% | $2.7B | 19% |
| BMY Bristol Myers Squibb Q2 FY26 Year over year +6% Operating margin −6% Net margin 26% | $13.0B | +6% | −6% | $3.3B | 26% |
| TMO Thermo Fisher Scientific Q2 FY26 Year over year +10% Operating margin 17% Net margin 14% | $12.0B | +10% | 17% | $1.7B | 14% |
| ABT Abbott Laboratories Q1 FY26 Year over year +8% Operating margin 12% Net margin 10% | $11.2B | +8% | 12% | $1.1B | 10% |
| AMGN Amgen Q2 FY26 Year over year +10% Operating margin 35% Net margin 24% | $10.1B | +10% | 35% | $2.4B | 24% |
| MDT Medtronic Q1 FY27 Year over year +14% Operating margin 18% Net margin 15% | $9.8B | +14% | 18% | $1.5B | 15% |
| GILD Gilead Sciences Q1 FY26 Year over year +4% Operating margin 37% Net margin 29% | $7.0B | +4% | 37% | $2.0B | 29% |
| SYK Stryker Q2 FY26 Year over year +9% Operating margin 25% Net margin 19% | $6.6B | +9% | 25% | $1.3B | 19% |
| DHR Danaher Q2 FY26 Year over year +6% Operating margin 18% Net margin 14% | $6.3B | +6% | 18% | $0.9B | 14% |
| BSX Boston Scientific Q2 FY26 Year over year +8% Operating margin 22% Net margin 17% | $5.4B | +8% | 22% | $0.9B | 17% |
| GEHC GE HealthCare Q1 FY26 Year over year +7% Operating margin 10% Net margin 8% | $5.1B | +7% | 10% | $0.4B | 8% |
| BDX Becton Dickinson Q3 FY26 Year over year −10% Operating margin 13% Net margin 8% | $5.0B | −10% | 13% | $0.4B | 8% |
| UHS Universal Health Services Q1 FY26 Year over year +10% Operating margin 11% Net margin 8% | $4.5B | +10% | 11% | $0.3B | 8% |
| REGN Regeneron Pharmaceuticals Q2 FY26 Year over year +17% Operating margin 30% Net margin 30% | $4.3B | +17% | 30% | $1.3B | 30% |
| IQV IQVIA Q1 FY26 Year over year +8% Operating margin 12% Net margin 7% | $4.2B | +8% | 12% | $0.3B | 7% |
| VTRS Viatris Q2 FY26 Year over year +5% Operating margin 0% Net margin – | $3.8B | +5% | 0% | – | – |
| LH Labcorp Q2 FY26 Year over year +6% Operating margin 12% Net margin 8% | $3.7B | +6% | 12% | $0.3B | 8% |
| DVA DaVita Q2 FY26 Year over year +5% Operating margin 16% Net margin 7% | $3.6B | +5% | 16% | $0.3B | 7% |
| HSIC Henry Schein Q2 FY26 Year over year +7% Operating margin 5% Net margin 3% | $3.5B | +7% | 5% | $0.1B | 3% |
| VRTX Vertex Pharmaceuticals Q2 FY26 Year over year +12% Operating margin 37% Net margin 33% | $3.3B | +12% | 37% | $1.1B | 33% |
| DGX Quest Diagnostics Q2 FY26 Year over year +10% Operating margin 15% Net margin 11% | $3.0B | +10% | 15% | $0.3B | 11% |
| BAX Baxter International Q2 FY26 Year over year +5% Operating margin 7% Net margin 4% | $3.0B | +5% | 7% | $0.1B | 4% |
| ISRG Intuitive Surgical Q2 FY26 Year over year +19% Operating margin 34% Net margin 28% | $2.9B | +19% | 34% | $0.8B | 28% |
| BIIB Biogen Q1 FY26 Year over year +2% Operating margin 19% Net margin 13% | $2.5B | +2% | 19% | $0.3B | 13% |
| ZTS Zoetis Q2 FY26 Year over year +0% Operating margin 35% Net margin 28% | $2.5B | +0% | 35% | $0.7B | 28% |
| SOLV Solventum Q2 FY26 Year over year +2% Operating margin 8% Net margin 4% | $2.2B | +2% | 8% | $0.1B | 4% |
| ZBH Zimmer Biomet Q2 FY26 Year over year +5% Operating margin 15% Net margin 9% | $2.2B | +5% | 15% | $0.2B | 9% |
| A Agilent Technologies Q3 FY26 Year over year +8% Operating margin 24% Net margin 19% | $1.9B | +8% | 24% | $0.4B | 19% |
| EW Edwards Lifesciences Q2 FY26 Year over year +14% Operating margin 29% Net margin 14% | $1.7B | +14% | 29% | $0.2B | 14% |
| WAT Waters Q2 FY26 Year over year +113% Operating margin −5% Net margin −8% | $1.6B | +113% | −5% | −$0.1B | −8% |
| STE Steris Q1 FY27 Year over year +7% Operating margin 19% Net margin 13% | $1.5B | +7% | 19% | $0.2B | 13% |
| RMD ResMed Q4 FY26 Year over year +9% Operating margin 31% Net margin 26% | $1.5B | +9% | 31% | $0.4B | 26% |
| DXCM Dexcom Q2 FY26 Year over year +13% Operating margin 24% Net margin 19% | $1.3B | +13% | 24% | $0.2B | 19% |
| INCY Incyte Q1 FY26 Year over year +21% Operating margin 24% Net margin 24% | $1.3B | +21% | 24% | $0.3B | 24% |
| IDXX Idexx Laboratories Q2 FY26 Year over year +10% Operating margin 35% Net margin 28% | $1.2B | +10% | 35% | $0.3B | 28% |
| COO Cooper Companies Q3 FY26 Year over year +1% Operating margin 21% Net margin 41% | $1.1B | +1% | 21% | $0.4B | 41% |
| ALGN Align Technology Q2 FY26 Year over year +4% Operating margin 15% Net margin 10% | $1.1B | +4% | 15% | $0.1B | 10% |
| MTD Mettler Toledo Q2 FY26 Year over year +4% Operating margin 33% Net margin 23% | $1.0B | +4% | 33% | $0.2B | 23% |
| VEEV Veeva Systems Q2 FY27 Year over year +18% Operating margin 30% Net margin 29% | $0.9B | +18% | 30% | $0.3B | 29% |
| WST West Pharmaceutical Services Q2 FY26 Year over year +14% Operating margin 21% Net margin 18% | $0.9B | +14% | 21% | $0.2B | 18% |
| PODD Insulet Q2 FY26 Year over year +24% Operating margin 16% Net margin 12% | $0.8B | +24% | 16% | $0.1B | 12% |
| RVTY Revvity Q2 FY26 Year over year +1% Operating margin 12% Net margin 7% | $0.7B | +1% | 12% | $0.1B | 7% |
| TECH Bio-Techne Q4 FY26 Year over year +1% Operating margin 23% Net margin 17% | $0.3B | +1% | 23% | $0.1B | 17% |
Diagrams
the 9 largestCost of revenue Operating expenses Tax and other Net profit
In the bar on each card, every block is its share of revenue.
-
UnitedHealthApr–Jun 2026 · reported Aug 10, 2026Revenue $112.0B +0% Net margin 5%
-
CVS HealthApr–Jun 2026 · reported Aug 5, 2026Revenue $106.1B +7% Net margin 3%
-
McKessonApr–Jun 2026 · reported Aug 5, 2026Revenue $105.4B +8% Net margin 1%
-
CencoraApr–Jun 2026 · reported Aug 5, 2026Revenue $84.8B +5% Net margin 1%
-
CignaApr–Jun 2026 · reported Jul 30, 2026Revenue $71.7B +7% Net margin 2%
-
Cardinal HealthOct–Dec 2025 · reported Feb 5, 2026Revenue $65.6B +19% Net margin 1%
-
CenteneApr–Jun 2026 · reported Jul 28, 2026Revenue $53.6B +10% Net margin 2%
-
Elevance HealthApr–Jun 2026 · reported Jul 15, 2026Revenue $50.5B +1% Net margin 3%
-
HumanaJan–Mar 2026 · reported Apr 29, 2026Revenue $39.6B +23% Net margin 3%
The rest of the sector
2 companiesNew results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.